Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Docetaxel in Docetaxel-resistant Prostate Cancer
NCT00728663Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2008
- Primary completion
- Sep 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in prostate cancer (PCa), sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00728663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00728663.